Pulse Biosciences (NASDAQ:PLSE) Upgraded to Sell by BidaskClub

BidaskClub upgraded shares of Pulse Biosciences (NASDAQ:PLSE) from a strong sell rating to a sell rating in a report released on Tuesday, BidAskClub reports.

Separately, Zacks Investment Research lowered Pulse Biosciences from a buy rating to a hold rating in a research report on Tuesday, August 18th.

Shares of NASDAQ PLSE opened at $11.67 on Tuesday. The stock has a market cap of $294.22 million, a price-to-earnings ratio of -5.01 and a beta of 1.90. The company has a current ratio of 7.91, a quick ratio of 7.91 and a debt-to-equity ratio of 0.26. Pulse Biosciences has a 1-year low of $5.11 and a 1-year high of $17.45. The stock’s 50-day moving average is $10.38 and its 200 day moving average is $9.15.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.03). On average, analysts forecast that Pulse Biosciences will post -1.98 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nuveen Asset Management LLC grew its position in Pulse Biosciences by 65.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 67,000 shares of the company’s stock worth $701,000 after acquiring an additional 26,605 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Pulse Biosciences by 22.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 32,934 shares of the company’s stock worth $345,000 after acquiring an additional 5,941 shares during the last quarter. Levin Capital Strategies L.P. grew its position in Pulse Biosciences by 26.7% during the 2nd quarter. Levin Capital Strategies L.P. now owns 19,000 shares of the company’s stock worth $199,000 after acquiring an additional 4,000 shares during the last quarter. Captrust Financial Advisors bought a new stake in shares of Pulse Biosciences in the 2nd quarter worth approximately $70,000. Finally, Bank of America Corp DE grew its position in shares of Pulse Biosciences by 14.9% in the 2nd quarter. Bank of America Corp DE now owns 20,076 shares of the company’s stock worth $210,000 after buying an additional 2,598 shares during the last quarter. Institutional investors and hedge funds own 11.63% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.

Featured Story: Quantitative Easing

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.